NDATOPICALGEL
Approved
Mar 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CONDYLOX (podofilox) is a topical gel small molecule indicated for the treatment of external genital warts in adults. It works by arresting mitosis in metaphase, causing necrosis of wart tissue. The product is applied directly by patients to affected areas.
$0.017BPart D
LOE ApproachingDeclining
With LOE approaching and minimal Part D utilization ($17K annually, 25 claims in 2023), this product faces significant commercial headwinds requiring defensive strategy and likely smaller, specialized commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CONDYLOX represents a mature, declining asset with minimal current hiring activity and limited career growth trajectory. Roles on this product typically involve defensive commercial strategy, cost management, and transition planning rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on CONDYLOX at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.